These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 16556509)

  • 1. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
    Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
    J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
    Masquelier B; Tamalet C; Montès B; Descamps D; Peytavin G; Bocket L; Wirden M; Izopet J; Schneider V; Ferré V; Ruffault A; Palmer P; Trylesinski A; Miller M; Brun-Vézinet F; Costagliola D;
    Antivir Ther; 2004 Jun; 9(3):315-23. PubMed ID: 15259894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
    Llibre JM; Bonjoch A; Iribarren J; Galindo MJ; Negredo E; Domingo P; Pérez-Alvarez N; Martinez-Picado J; Schapiro J; Clotet B;
    HIV Med; 2008 Aug; 9(7):508-13. PubMed ID: 18484978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
    Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
    HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
    Margot NA; Lu B; Cheng A; Miller MD;
    HIV Med; 2006 Oct; 7(7):442-50. PubMed ID: 16925730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
    Cervero M; Torres R; Jusdado JJ; Rodríguez-Rosado R; Del Alamo M; García-Benaya E
    Enferm Infecc Microbiol Clin; 2006; 24(7):426-30. PubMed ID: 16956530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.